pfizer glp 1 drug Danuglipron Pfizer secures rights to new

First-time prescribing of ADM tirzepatide also decreased (-7.9%), as did first-time prescribing of AOM tirzepatide (-9.5%) as well

The widespread use of GLP-1 therapies, particularly in obesity, has raised questions about appropriate prescribing, long-term safety, and equitable access

This work has included pharmacokinetic optimization, with steps to prevent peptide inactivation and to extend the pharmacodynamics to minimize the number of injections required for therapeutic effect

49 LiQ.ZhaoY.GuoH.LiQ.YanC.LiY.et al (2023)

Interestingly, agmatine, a metabolite produced by the gut bacterium Bacteroides vulgatus was shown to impair ovarian function by inhibiting GLP-1 secretion through activation of the farnesoid X receptor (FXR) (Yun et al., 2024)